Russia Unveils Promising Cancer Vaccine ‘Enteromix’ After Successful Preclinical Trials
The vaccine is initially being developed to combat colorectal cancer, one of the most common and deadly cancers worldwide.
VLADIVOSTOK: Russia has announced a breakthrough in cancer treatment with the development of an experimental vaccine, Enteromix, which has successfully completed preclinical trials. The news was shared by Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), at the Eastern Economic Forum in Vladivostok.
Skvortsova stated that the vaccine is “now ready for use,” pending official regulatory approval. The experimental drug has shown significant results in animal models, with tumour size reductions ranging from 60% to 80%, depending on the cancer type, along with notable improvements in survival rates.
Initial Focus: Colorectal Cancer
The vaccine is initially being developed to combat colorectal cancer, one of the most common and deadly cancers worldwide. Additionally, research is underway to create versions targeting glioblastoma—a highly aggressive brain cancer—and melanomas, including rare ocular melanoma.
Some media outlets claimed the vaccine showed 100% efficacy in trials, although this has not yet been independently verified. Newsweek, among others, noted it could not confirm those claims.
While human trials and a public release timeline have not been officially announced, Skvortsova’s remarks indicate that Russia may soon seek regulatory clearance for the vaccine’s next phase.
If proven effective in humans, Enteromix could represent a major advance in the global fight against cancer, offering new hope for patients with some of the most challenging forms of the disease.
Comments are closed, but trackbacks and pingbacks are open.